In response to concerns by physicians and other clinicians about their readiness to comply with the Medicare Access and CHIP Reauthorization Act (MACRA), which began Jan. 1, the Centers for Medicare and Medicaid Services (CMS) has revised implementation requirements by adopting four options that will allow providers to choose the level and pace at which they comply.
The U.S. Food and Drug Administration has approved the first human trial of an experimental Zika virus vaccine.
In the first overhaul of managed care in Medicaid and the Children’s Health Insurance Program, the Department of Health and Human Services issued a final rule in an effort to deliver better care, smarter spending and healthier people.
The Centers for Medicare and Medicaid Services finalized changes to how it evaluates whether Medicare accountable care organizations are saving money.
Research conducted at the University of Texas at Austin found that how the influenza (flu) vaccine produces antibodies to protect against disease could be used to improve the vaccine.
Kamada has initiated a Phase II clinicaltrial with its proprietary Alpha-1Antitrypsin (AAT) for the prevention oflung transplant rejection.
Sandoz announced the U.S. market introduction of rosuvastatin calcium tablets, a generic version of Crestor by AstraZenica Pharmaceuticals LP.
The U.S. Food and Drug Administration approved bezlotoxumab (Zinplava, Merck) to prevent the recurrence of Clostridium difficile (C. diff) infection (CDI) in patients aged 18years and older.
The U.S. Food and Drug Administration has approved Erelzi (etanercept-szzs), the first biosimilar etanercept, for all indications included in the reference product’s label.
The Department of Health and Human Services awarded nearly $156 million in funding to support 420 health centers in 47 states, the District of Columbia and Puerto Rico to increase access to integrated oral healthcare services and to improve oral health outcomes for Health Center Program patients.
The U.S. Food and Drug Administration has approved Amgen’s Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for the treatment of several autoimmune conditions.
The U.S. Food and Drug Administration has approved Gilead Sciences’ Vemlidy (tenofovir alafenamide,TAF) 25 mg once-daily treatment for adults with chronic hepatitis B virus(HBV) infection with compensated liver disease.
